Modulating the activity of tumor-infiltrating dendritic cells (TiDCs) provides opportunities for novel cancer interventions. In this study, we report on the uptake of mRNA by CD8α + crosspresenting TiDCs upon its intratumoral (IT) delivery. We exploited this property to deliver mRNA encoding the co-stimulatory molecule CD70, the activation stimuli CD40 ligand, and constitutively active Toll-like receptor 4, referred to as TriMix mRNA. We show that TiDCs are reprogrammed to mature antigen-presenting cells that migrate to tumor-draining lymph nodes (TDLNs). TriMix stimulated antitumor T-cell responses to spontaneously engulfed cancer antigens, including a neoepitope. We showed in various mouse cancer models that IT delivery of TriMix mRNA results in systemic therapeutic antitumor immunity. Finally, we showed that the induction of antitumor responses critically depends on TiDCs, whereas it only partially depends on TDLNs. As such we provide a platform and a mechanistic rationale for the clinical testing of IT administration of TriMix mRNA.
Introduction
The tumor microenvironment exerts suppressive influences on tumor-infiltrating dendritic cells (TiDCs) and as such prevents induction of antitumor immunity (1, 2) . It has been proposed that adjuvants like Toll-like receptor (TLR) ligands and agonistic antibodies to CD40 can restore the function of TiDCs (3) (4) (5) . However, adjuvants are not TiDC-specific and could therefore evoke adverse effects when administered in an untargeted fashion. For example, intratumoral (IT) delivery of TLR4 ligands induces tumor cell-resistance to cytotoxic Tlymphocytes (CTLs) and CD40-stimulation induces neoangiogenesis of tumor blood vessels (6, 7) . Consequently, strategies need to be developed that exclusively act on TiDCs, preferably on CD8α + TiDCs, which are critical for the stimulation of antitumor immunity (8, 9) .
Several strategies have been developed to target adjuvants like TLR ligands or IL-12, together with antigens, to cross-priming DCs (10) (11) (12) (13) (14) (15) . Often these exploit antibodies or nanobodies to surface markers differentially expressed by DC-subsets (13, 15). Such markers include C-type lectin receptors like DEC205 and DC-SIGN (11, 12) . In other cases, like in the use of DCspecific nanobodies, the target is unknown (16). These targeting moieties selectively direct the adjuvant and antigen to DCs, resulting in induction of antigen-specific immunity. However, the adjuvant and antigen coupled to isotype-matched antibodies (conjugate or nanoparticle format) or irrelevant nanobodies (lentiviral vector) evoke T-cell stimulation, albeit it to a lesser extent (11, 12, 16) . This is attributed to the ability of DCs to ingest antigens through various mechanisms. Thus, overall these strategies are not as "targeted" as anticipated. Moreover, none of these studies addressed whether adjuvants could be selectively delivered to crosspriming TiDCs without co-delivery of antigens.
We developed an mRNA-based adjuvant, consisting of three mRNA molecules encoding the co-stimulatory molecule CD70, the activation stimulator CD40 ligand (CD40L), and constitutively active TLR4 (caTLR4), referred to as TriMix mRNA (17) . Delivery of tumorassociated antigen (TAA) and TriMix mRNA to DCs, ex vivo or in situ, reprograms them to on December 18, 2017. © 2015 American Association for Cancer Research. cancerimmunolres.aacrjournals.org Downloaded from Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on December 11, 2015 ; DOI: 10.1158/2326-6066.CIR-15-0163 mature antigen-presenting cells (18, 19) . These DCs and the T cells they activate are protected from regulatory T cells (Tregs) (20). These observations, together with the fact that mRNA as a biopharmaceutical fulfills all requirements of an optimal adjuvant, prompted us to evaluate whether IT delivery of TriMix mRNA is a feasible strategy to activate TiDCs and as such induce antitumor immunity.
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Tumor cell inoculation and IT delivery of mRNA
Mice were injected subcutaneously (50 µl) with 2 x 10 4 TC-1 cells or 5 x 10 5 E.G7-OVA, P815 or A20 cells at the lower back or both flanks. Tumors that reached a volume of ±100mm 3 as measured by caliper and determined by the formula for a prolate ellipsoid were injected with mRNA resuspended in 50 μl 0.8 Hartmann solution (23) .
In vivo bioluminescence imaging (BLI)
To assess IT delivery of mRNA and the cells involved in its uptake, tumors grown in wild-type, Batf-3 -/or CD11c-DTR mice were injected with 10 µg FLuc mRNA. CD11c-DTR mice were treated a day before mRNA delivery with PBS or 4 ng diphtheria toxin (DT)/gram bodyweight (Sigma-Aldrich, Belgium). In vivo BLI was performed at the indicated time points (24) .
Tracking of in vivo mRNA transfected cells
Twenty-four hours before their isolation, tumors were injected with 10µg Thy1.1 mRNA. Single cells were stained with antibodies specific for Thy1.1 coupled to phycoerythrin (PE) (clone OX7, Becton Dickinson [BD], Belgium), CD11c-AlexaFluor647 (clone N418; Biolegend, Belgium), CD11b-fluorescein isothiocyanate (FITC) (clone M1/70, BD), CD90.2-FITC (clone 30H-12; BD) and F4/80-biotin (prepared in-house and detected with streptavidin-FITC [BD]).
Staining was performed in the presence of antibodies to CD16/CD32 (BD). Data were collected on the BD LSR Fortessa flow cytometer and analyzed using FACSDiva software (BD). Samples stained with isotype-matched antibodies were used to delineate Thy1.1 + cells.
In vivo proliferation assay
A day before treatment, 1 x 10 6 MACS-sorted (Miltenyi Biotec, Germany) and 0.5 μM carboxyfluorescein succinimidyl ester (CFSE)-labeled (Life Technologies) CD8 + OT-1 T cells were injected intravenously (200 µl PBS). Tumors were treated with 40 µg tNGFR mRNA, 10 µg tNGFR and 30 µg TriMix mRNA (10 µg/component), 10 µg OVA and 30 µg TriMix mRNA, or 10 µg OVA and 30 µg tNGFR mRNA. The presence and phenotype of CFSE low T cells in tumor-draining lymph nodes (TDLNs) and tumors was analyzed five days later by flow cytometry. Cells were stained with Peridinin-chlorophyll proteins (PerCP-Cy5.5)-conjugated antibodies to CD8 (clone 53-6.7, BD) together with antibodies to CD62L-PE-Cy7 (clone MEL-14, BD) and CD44-AF647 (clone IM7, BioLegend), antibodies to CD25-PE (clone 3C7, BD) and CD69-allophycocyanin (APC) (clone H1.2F3, BD), or antibodies to CD27-APC (clone
LG.7F9, eBioscience, Austria) and PD-1-PE (clone RMPI-30, BioLegend). Perforin was stained intracellularly using antibodies to perforin-PE (clone eBIOMAK-D, eBioscience).
Isotype-matched antibodies (BD) were used to verify staining specificity and to delineate positive populations. Data were collected using the BD LSR Fortessa flow cytometer.
Analyses were performed with FACSDiva software (BD). A light scatter gate excluding death lymphocytes and additional gating on CD8 + CFSE low cells was used.
IFNγ ELISPOT assay
Tumors were injected with 30 µg tNGFR or TriMix mRNA (10 µg/component). Five days later, CD8 + T cells were MACS-sorted from TDLNs. CD8 + T cells (2 x 10 5 ) were stimulated in duplicate for three days with 5 µM of the appropriate peptide in a 96-well multiscreen PVDFmembrane plate (Millipore, Germany). Control peptides and CD8 + T cells obtained from LNs of naive mice were used for comparison. As a positive control CD8 + T cells were stimulated with mouse CD3/CD28 antibody-coated beads (1/100, Invitrogen). The ELISPOT was performed following the manufacturer's instructions (Cell Sciences, USA). Sciences, Belgium) by oral gavage (200 µl) four hours before treatment. The in vivo cytotoxicity assay was performed as described (19) .
In vivo cytotoxicity assay

Therapy experiments
Tumors were injected with 30µg tNGFR or TriMix mRNA (10 µg/mRNA), or 20 µg tNGFR and 10 µg caTLR4 mRNA. When indicated, mice received 25 µg FTY-720 as described above.
Tumor length and width were measured using a caliper and volumes calculated using the formula for a prolate ellipsoid. Mice were killed when tumors exceeded 1500 mm 3 .
In vivo migration of DCs
Bone marrow-derived DCs were electroporated with 10µg FLuc or eGFP mRNA (25) . Four hours before injecting 30 µg tNGFR or TriMix mRNA, 2 x 10 6 DCs (50 µl) were administered to tumors. Migration of FLuc + or eGFP + DCs to TDLNs was evaluated 24 hours later using ex vivo BLI on TDLNs or flow cytometry analysis on cell suspensions of TDLNs, respectively (26) .
Staining was performed after blocking Fc-receptors with CD16/CD32 antibodies, using anti-CD11c-AF647, biotinylated anti-CD40 (clone FGK45) and anti-CD86 (clone GL-1).
Biotinylated antibodies were prepared in-house and detected with SA-PerCP-Cy5.5 (BioLegend) or SA-eFluor450 (eBioScience). Isotype-matched antibodies served as controls (BD). Data were collected and analyzed as described in Supplementary Fig. S1 .
In vitro proliferation assay
Tumors were injected with 30 µg tNGFR or TriMix mRNA (10 µg/component). Three days later, CD11c + cells were MACS-enriched from TDLNs. These were co-cultured in duplicate at a 1:10 ratio with 2 x 10 5 MACS-sorted and 0.5 μM CellTraceViolet-labeled CD8 + OT-1 cells (Life Technologies). Cell proliferation was analyzed three days later by flow cytometry.
Supernatants were screened in a sandwich ELISA for the presence of IFN-γ (eBioscience). 
Statistical analyses
Results
CD8α + TiDCs engulf mRNA
To address whether cells in the tumor microenvironment engulf mRNA, we injected tumors of different histological origin in genetically distinct immunocompetent hosts with FLuc mRNA. In vivo BLI was performed 24 hours later, showing FLuc-expression in E.G7-OVA, P815, TC-1 and A20 tumors ( Fig. 1A) . Fluorescence at the tumor site was readily detectable in the E.G7-OVA model for about 10 hours ( Fig. 1B) . Flow cytometry was performed on cell suspensions of P815 tumors injected with Thy1.1 mRNA, showing that a small percentage of mainly CD11c + cells were Thy1.1 + (data not shown). Mice bearing E.G7-OVA-CD11c-DTR tumors were treated with diphtheria toxin to deplete CD11c + cells. Uptake of mRNA, as assessed by BLI, was inhibited, which confirmed the role of CD11c + cells (Fig. 1C ). In vivo BLI performed on E.G7-OVA-bearing Batf-3 -/mice, which lack CD8α + DCs, showed significantly reduced radiance compared to wild-type mice, showing that these cross-presenting DCs are mainly responsible for mRNA uptake (Fig. 1D ).
TriMix stimulates functional tumor-specific T cells
As cross-presenting CD8α + TiDCs are at least partially responsible for mRNA uptake, we evaluated whether IT delivery of TriMix mRNA results in stimulation of tumor-specific T cells ( Fig. 2 ). We first assessed proliferation by transferring CFSE-labeled CD8 + OT-1 cells into E.G7-OVA-bearing mice and studying their expansion. The OT-1 T cells in the TDLNs of mice treated with TriMix mRNA expanded significantly more than OT-1 cells in mice treated with tNGFR mRNA. Immunization with antigen mRNA alone did not result in a significant change in proliferation compared to immunization with the tNGFR mRNA, hinting that TiDCs have access to TAAs but are dysfunctional. Moreover, co-administration of OVA and TriMix mRNA did not boost OT-1 expansion compared to TriMix delivery alone ( Fig. 2A ). Nonetheless, antigen presentation is critical, as IT injection of TriMix mRNA in mice bearing EL4 tumors (OVA -) did not induce significant proliferation of OT-1 cells ( Supplementary Fig. S2A ). Second, we analyzed the phenotype of proliferating OT-1 cells in E.G7-OVA-bearing mice treated with tNGFR or TriMix mRNA. These were CD25 + CD44 high CD69 + CD62L low in both TDLNs and tumors irrespective of the treatment. However, CFSE low OT-1 cells in tumors were CD27 -PD-1 + , which is in contrast to those in TDLNs. CFSE low OT-1 cells in TriMix-treated mice showed a higher expression of perforin compared to those in mice treated with tNGFR mRNA (81.2 ± 1.2% and 44.8 ± 2.8%, respectively, P < 0.001) ( Supplementary Fig. S2B -C).
Therefore, we next evaluated the ability of IT TriMix mRNA delivery to induce tumor-specific CTLs and compared it to CTL-induction after delivery of caTLR4 or tNGFR mRNA ( Fig. 2B ).
Whereas caTLR4 or tNGFR mRNA injection induced specific lysis of target cells of 8.2 ± 2.0% and 3.7 ± 0.9% respectively, we found that IT injection of TriMix mRNA led to 69.0 ± 1.2% of specific lysis, indicating induction of more CTLs. We also evaluated whether addition of OVA mRNA to TriMix would lead to a higher induction of CTLs, but found this was not the case. We confirmed these results in the P815 model ( Fig. 2C) , where we found that we could induce CTLs against P1A, a cancer-testis antigen, and P1E, a tumor-specific antigen resulting from a mutation in the methionine sulfoxide reductase gene.
Finally, we evaluated the capacity of the stimulated T cells to produce IFNγ upon restimulation using ELISPOT, and found that there was a significantly higher number of IFNγ producing CD8 + T cells in TriMix mRNA-treated mice, compared to tNGFR mRNA-treated mice in both the P815 ( Fig. 2D ) and E.G7-OVA ( Supplementary Fig. S2D ) models.
IT delivery of TriMix mRNA significantly delays tumor growth
We next assessed the therapeutic potential of IT TriMix mRNA delivery. We showed prolonged survival in mice treated with TriMix mRNA compared to mice treated with tNGFR mRNA in various tumor models ( Fig. 3A-D) . When we evaluated the effect of IT injection of caTLR4 mRNA in the P815 model, we observed that these tumors followed the same growth curve as tumors treated with tNGFR mRNA (data not shown). Encouraged by the results obtained with TriMix mRNA, we next used a two-sided tumor model. Herein, only the left tumor was treated while the contra-lateral tumor (the "control" in 
Antitumor immunity upon IT delivery of TriMix mRNA depends on DCs
To study the role of TiDCs in the outcome of IT delivery of TriMix mRNA, we used E.G7-OVAbearing Batf-3 -/mice, which lack splenic CD8α + DCs. The therapeutic effect of IT injection of TriMix mRNA in these mice was dampened ( Fig. 5A-B ). The lower therapeutic benefit in mice lacking CD8α + DCs was explained by their lower CTL stimulation, as shown in an in vivo cytotoxicity assay ( Fig. 5C ). Similarly, CTL-induction upon IT delivery of TriMix mRNA was abrogated when mice lacked CD11c + cells ( Fig. 5D ).
Stimulation of T cells upon IT delivery of TriMix mRNA occurs in TDLNs
We next addressed whether CTLs are activated in the tumor and/or in the TDLNs. These data, however, do not exclude the possibility that T cells are activated at the tumor site as well. Therefore, we evaluated the induction of CTLs in E.G7-OVA-bearing mice treated with tNGFR or TriMix mRNA from which the TDLN had been resected three days before treatment.
CTL-induction in these mice was dramatically decreased (Fig. 7A) . Nonetheless, mice from which the TDLNs were removed and that were treated with TriMix mRNA showed a prolonged survival ( Fig. 7B ), suggesting that tumor-infiltrating T lymphocytes (TILs) could be re-activated upon IT delivery of TriMix mRNA. To study this, we pre-treated tumor-bearing mice with FTY-720, an agonist of the sphingosine 1-phosphate receptor that abrogates the egress of T cells (27) . In these mice, treatment of tumors with TriMix mRNA did not stimulate tumor-specific CTLs (Fig. 7C) . FTY-720 pre-treatment only marginally affected the therapeutic potential of IT treatment with TriMix mRNA, supporting the hypothesis that IT delivery of TriMix mRNA results in de novo activation of tumor-specific T cells as well as re-activation of TILs (Fig. 7D ). 
Discussion
In most human and mouse solid cancers the tumor microenvironment is infiltrated with DCs. These TiDCs acquire TAAs; however, they are unable to present them to and properly activate CTLs. This dysfunction is due to immunosuppressive factors present in the tumor microenvironment (28) . Several strategies aimed at improving the function of TiDCs have been developed. Examples are the use of TLR agonists and agonistic CD40 antibodies.
However, TLRs and CD40 are not exclusively expressed on DCs and negative signaling resulting in tumor immune escape and tumor cell dissemination has been described (3, 6, 7) .
Consequently, strategies need to be developed that mediate selective activation of TiDCs.
Here, we show that TriMix mRNA reprograms CD8α + TiDCs in vivo into stimulatory cells that efficiently process spontaneously engulfed TAAs, up-regulate co-stimulatory molecules, and migrate to TDLNs to activate CTLs. Moreover, we provide evidence that IT delivery of TriMix mRNA results in re-activation of TILs. Together, this results in a delay in growth of established tumors.
We showed that upon IT delivery of mRNA, the encoded antigen is mostly but not exclusively expressed in Batf-3-dependent CD11c + cells. This finding is consistent with several studies showing that Batf-3 -/mice, which lack CD8α + cross-presenting DCs, fail to clear highly immunogenic tumors (8, 9) . Our study confirms that CD8α + TiDCs have spontaneously acquired TAAs but fail to induce antitumor immunity, unless activated with TriMix mRNA. We furthermore show that induction of CTLs and control of tumor growth is exerted by Batf-3dependent CD8α + DCs as well as CD11c + Batf-3-independent cells. Based on the current knowledge on DC subsets (15), we contend that CD11b + CD11c + DCs could play a role, despite their weak in vitro stimulatory properties (29) .
Our work further suggests that IT delivery of TriMix mRNA results in de novo activation of tumor-specific CTLs and re-activation of TILs. Broz et al (29) also showed that Batf-3dependent cells play a key role in re-activating TILs. Whereas that study shifts the emphasis for T-cell control from TDLNs to tumors, our data show that both the tumor and TDLNs are critical for CTL-induction (30) (31) (32) . However, we cannot exclude that de novo T cells trigger a cascade of events at the tumor, resulting in revival of TILs, as previously proposed (33) .
Therefore, we suggest that IT delivery of TriMix mRNA activates tumor-specific T cells de novo and results in re-activation of TILs, probably because of their contact with TriMixmodified TiDCs as well as a cascade of TIL-reviving events instigated by de novo tumor-
specific T cells.
A key point is that the activation of CTLs upon IT delivery of TriMix mRNA depends on the spontaneous acquisition of TAAs by TiDCs, avoiding the need to prime TiDCs with exogenous TAAs. Intratumoral delivery of TriMix eliminates the challenge presented trying to define the best-suited TAA for vaccination. In this regard cancer-testis and differentiation antigens are often used. These are self-proteins and are thus subjected to tolerance mechanisms. In contrast, mutated antigens are not in the cross-line of tolerance mechanisms (34) (35) (36) .
Therefore, the use of the tumor's antigenic repertoire, including neo-epitopes, is an attractive approach. We provide evidence that IT delivery of TriMix mRNA induces CTLs specific for cancer-testis antigens as well as for a neo-epitope. TriMix-activated TiDCs thus have the potential to present a variety of antigens that they acquire at the tumor site.
Large numbers of tumor-specific T cells expanded in mice treated with TriMix mRNA, relative to the expansion in mice treated with tNGFR mRNA. The T cells had a comparable phenotype, characterized by high expression of CD25, CD44, and CD69, and low expression of CD62L and CD27. It is suggested that CD27 -T cells represent a memory subset with cytolytic capacity (37) . In this regard, we observed that perforin-expression was significantly higher in mice treated with TriMix mRNA. Therefore, it is not surprising that tumor-bearing mice treated with TriMix mRNA were able to delay tumor growth, whereas mice treated with tNGFR mRNA were not. This could be attributed to the lower expansion of perforin positive tumor-specific T cells. Alternatively, one could argue that CTLs stimulated after IT delivery of TriMix mRNA are (partially) protected from suppressive mechanisms exerted in the tumor microenvironment. This hypothesis is supported by a previous study showing that CD8 + T cells activated by TriMix mRNA-modified DCs were protected from Tregs (20). Although we did not study T-cell trafficking in detail, our data on the outgrowth of tumors in the two-sided tumor model further suggest that tumor-specific CTLs efficiently screen the body for tumors, irrespective of whether the primary tumor was cured.
The promise of many cancer immunotherapies is often hampered by the difficulties regarding its targeted in situ delivery. In our approach, however, CD8α + TiDCs are the target, and these cells were shown to engulf and translate mRNA dissolved in Hartmann's solution. Most likely the mRNA uptake is mediated by macropinocytosis as described for the mRNA uptake by intranodal DCs (38) . Consequently, when targeting DCs in situ, mRNA is an attractive vector as it enables selective delivery without prior manipulation. The mRNA itself can trigger several pattern recognition receptors (PRRs) (39), whose activation negatively affects its translation, implying that stronger TiDC-activation could be obtained using "modified" mRNA that does not trigger PRRs (40) (41) (42) . If PRRs are triggered, the effects observed in this study may be due to the delivery of mRNA rather than the delivery of TriMix mRNA. However, when using equal amounts of tNGFR or caTLR4 mRNA, no strong induction of CTLs or therapeutic benefit were seen. These data highlight the added benefit of TriMix mRNA, even if mRNA were to trigger PRRs.
In conclusion, we provide proof-of-concept for the use of TriMix mRNA in IT delivery and as such, propose a novel cancer immunotherapy that exploits cross-presenting DCs and the Tumors that reached a size of ± 100 mm 3 were injected with 30 µg tNGFR or TriMix mRNA.
Mice were killed when tumors reached a size of ± 1500 mm 3 . The survival curves depict pooled results from at least 2 independent experiments with 5 to 7 mice/group in each experiment. were inoculated with tumor cells at both flanks. Once both tumors reached a size of ±100mm 3 , the left tumor was injected with 30 µg tNGFR or TriMix mRNA. A and C, the growth of respectively A20 and P815 tumors after treatment with tNGFR or TriMix mRNA is shown for the treated and distant non-treated tumors. B and D, the survival of mice bearing respectively A20 or P815 tumors is shown. Results from 2 experiments with 6 mice/group were pooled for the P815 model. One experiment with 4 mice/group was performed for the A20 model. 
